CMND Advances CMND-100 Phase I/IIa Trial to Third Cohort After DSMB Approval, 80mg Dose, Multinational Sites Including Johns Hopkins, Tel Aviv, Hadassah, Non-Hallucinogenic Neuroplastogen for Alcohol Use Disorder, Favorable Safety Profile, No Serious Adverse Events, Full Treatmen
Clearmind Medicine Inc. Common Shares · Now $3.17
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS